Celgene Corporation (CELG) discovers, develops, and commercializes therapies to treat cancer and inflammatory diseases worldwide. It markets REVLIMID, an oral immunomodulatory drug for multiple myeloma, myelodysplastic syndromes (MDS), and mantle cell lymphoma
The sales have gone up from a year ago about 16%, but the earnings have gone up 23%.
For 2017, Celgene upped its earnings outlook from a range of $7.10 – $7.25 per share to a range of $7.15 – $7.30 per share. Compared to 2016 EPS 5.94, the growth rate is about 20%. PE now is 119.52/5.94 = 20.
PEG = 20/20 = 1.
PE for 2017 is 119.52/7.1= 16.8.
Hold for long-term investment.
read at
http://files.shareholder.com/downloads/AMDA-262QUJ/4363263130x0x805901/a572090b-29e5-48e4-bf42-a4754a8c5640/EPS.pdf
Note: the data at MorningStar is wrong !
EPS is 2.49 there, read at
http://financials.morningstar.com/income-statement/is.html?t=CELG®ion=usa&culture=en-US.
Share prices is now 118.85, a – 2.9% drop from previous day !
I do not find any reason so far.
The following reason actually presents a good chance to buy more, as its partner failed on drup which Celgene was not even counting on until before 2019.
Why Shares of Biopharma Giant Celgene (CELG) Tumbled Today
read at
https://finance.yahoo.com/news/why-shares-biopharma-giant-celgene-210609093.html
A Strong Case for Buying Celgene
read at
https://www.fool.com/investing/2017/05/05/a-strong-case-for-buying-celgene.aspx?yptr=yahoo
Celgene just reported 2017Q1 results. It looks good compared to a year ago, but the share prices dropped 1% to about 124. The share prices have not moved much in the past few weeks.
The main reason is likely that for 3 quarters the sales have been almost flat, no much growth.
Celgene’s Deep Pipeline Can Reassure Investors
read at
https://www.thestreet.com/story/14032637/1/celgene-s-deep-pipeline-can-reassure-investors.html?puc=yahoo&cm_ven=YAHOO&yptr=yahoo
A Phase 4 Win For Otezla: How Much Help For Celgene?
http://seekingalpha.com/article/4052339-phase-4-win-otezla-much-help-celgene
As expected, Celgene share prices have started to rise for the mid- to long-term !
The same for IBB, the biotech sector as a whole.
Celgene: A ‘Fuggedaboutit’ Core Biotech Holding, read at
http://seekingalpha.com/article/4048903-celgene-fuggedaboutit-core-biotech-holding
3 Great Stocks to Buy Instead of NVIDIA Corporation
read at
https://www.fool.com/investing/2017/02/21/3-great-stocks-to-buy-instead-of-nvidia-corporatio.aspx?source=yahoo-2-news&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2-news&yptr=yahoo
How does Celgene stack up against biotech index IBB ?
Almost the same from the day Trump was elected US President (2016.11.07) to now 2017.02.22, but up more in one year time.
As can be seen in the chart, biotech and Celgene are likely to play the catch up game.
Celgene 2016Q4 and annual report have very encouraging outlook to 2017 and 2020.
Good for long term investment .
http://files.shareholder.com/downloads/AMDA-262QUJ/3860261584x0x925311/AD0A0DEF-D074-473E-80F0-7470B32A62DF/Q4_2016_EPS_Deck_-_FINAL.pdf
Adjust earnings per share is usd 5.94 for 2016 and forecasted to be 7.1 – 7.25 for 2017.
PE now is 115.61 / 5.94 = 19.5 ; and 115.61 / 7.1 = 16.3 for 2017. EPS growth rate is 7.1/5.94 =19% .
Celgene is one of the best bio stocks to own at this moment.
3 Biggest Risks for Celgene Corporation , read at
http://www.fool.com/investing/2016/12/15/3-biggest-risks-for-celgene-corporation.aspx
It will announce 2016Q4 results on 2017.1.26
Celgene has been growing impressively every year.
The price / earnings ratio is about 22 , read at
http://data.cnbc.com/quotes/celg/tab/5
The stock prices have been growing also .
Good company to consider buying for long-term investment.